The ESC Handbook on Cardiovascular Pharmacotherapy

 
 
Oxford University Press
  • 2. Auflage
  • |
  • erschienen am 16. Mai 2019
  • |
  • 904 Seiten
 
E-Book | PDF mit Adobe-DRM | Systemvoraussetzungen
978-0-19-107813-2 (ISBN)
 
This European Society of Cardiology (ESC) Handbook on Cardiovascular Pharmacotherapy has been developed by experts from the ESC Working Group on Cardiovascular Pharmacotherapy. Its recommendations are aligned with the ESC Clinical Practice Guidelines and based on the most recent scientific evidence in cardiovascular pharmacology and pharmacotherapy. The Handbook provides up-to-date information on pharmacotherapy for cardiovascular disease prevention, and treatment of cardiovascular disease, including ischaemic heart disease, heart failure, arrhythmias, and structural heart disease. The Handbook also deals with the important problems of cardiovascular pharmacotherapy in pregnancy and lactation, kidney insufficiency, and liver disease as well as focusing on major drug interactions, a topic of extreme importance in clinical practice. Two large sections of the book provide a comprehensive A-Z formulary of cardiac and non-cardiac pharmacological agents with practical and accessible information on the most important pharmacological aspects of these agents and their use in clinical practice. The Handbook represents essential reading for cardiologists, general practitioners, internal medicine specialists, anaesthetists, clinical pharmacologists, geriatricians, obstetricians, and cardiovascular nurse consultants. Junior doctors and trainees in all these specialties are also likely to find this book of help. The print edition comes with full access to the online version that will be updated at yearly intervals to keep it up to date.
2. Auflage
  • Englisch
  • Oxford
  • |
  • Großbritannien
  • 53,07 MB
978-0-19-107813-2 (9780191078132)
weitere Ausgaben werden ermittelt
Professor Kaski is the Immediate Past Director of the Cardiovascular and Cell Sciences Research Institute, St George's, University of London. He is Doctor of Science, University of London, Fellow of the Royal College of physicians (London), the European Society of Cardiology, the American College of Cardiology and the American Heart Association, among over 20 other scientific societies worldwide. He is Deputy Editor in Chief, International Journal of Cardiology, Editor in Chief, European Cardiology Review and the Cardiovascular Pharmacotherapy book series, ISCP. Professor Kjeldsen is author of over 200 papers and multiple books. Presenter of over 100 lectures nationally and internationally, he is Chairman at 45 scientific sessions. He has extensive experience as peer reviewer at scientific journals, from editorial boards, as chairman and organizer of meetings and congresses and as examiner of theses and research projects nationally and internationally. Teaching interests include Cardiology, cardiovascular pharmacology, and research methodology.
  • Cover
  • Half-Title
  • Title
  • Imprint
  • Preface
  • Contents
  • Contributors
  • Symbols and Abbreviations
  • Class of recommendations and levels of evidence
  • Section 1 Cardiovascular disease prevention
  • 1.1 Hypertension
  • 1.2 Dyslipidaemia
  • 1.3 Metabolic syndrome and diabetes
  • 1.4 Thrombosis
  • Section 2 Ischaemic heart disease
  • 2.1 Acute coronary syndrome: STEMI and NSTEMI
  • 2.2 Chronic stable angina
  • 2.3 Coronary artery spasm and microvascular angina
  • 2.4 Takotsubo syndrome
  • Section 3 Heart failure
  • 3.1 Heart failure
  • 3.2 Heart transplantation
  • Section 4 Arrhythmias
  • 4.1 Atrial fibrillation
  • 4.2 Supraventricular (narrow complex) tachycardias
  • 4.3 Ventricular arrhythmias
  • 4.4 Bradyarrhythmias
  • 4.5 Syncope
  • Section 5 Structural heart disease
  • 5.1 Valvular heart disease
  • 5.2 Myocarditis and pericardial syndromes
  • 5.3 Cardiomyopathy
  • 5.4 Pulmonary hypertension
  • Section 6 Management of cardiovascular disease in pregnancy and lactation and in the presence of comorbidities
  • 6.1 Kidney disease
  • 6.2 Pregnancy and lactation
  • 6.3 Liver disease
  • Section 7 Major drug interactions
  • 7.1 Major drug interactions
  • Section 8 Cardiovascular drugs-from A to?Z
  • 8.1 Cardiovascular drugs-from A to?Z
  • Section 9 Non-?cardiac drugs affecting the heart-from A to?Z
  • 9.1 Non-?cardiac drugs affecting the heart-from A to?Z
  • Index

Dateiformat: PDF
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Bitte beachten Sie bei der Verwendung der Lese-Software Adobe Digital Editions: wir empfehlen Ihnen unbedingt nach Installation der Lese-Software diese mit Ihrer persönlichen Adobe-ID zu autorisieren!

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Download (sofort verfügbar)

51,99 €
inkl. 5% MwSt.
Download / Einzel-Lizenz
PDF mit Adobe-DRM
siehe Systemvoraussetzungen
E-Book bestellen